New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’

More than 2 Million Americans Infected Each Year, 23,000 Die from Antibiotic-Resistant Bacteria

Novoclem Therapeutics, a biotech company focused on advancing nitric oxide therapies for the treatment of respiratory diseases, today announced that data from an in vitro study with BIOC51, a nitric oxide-releasing biopolymer being developed for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients, will be presented at the 2017 ID Week conference in San Diego, California this week.